Stohl William
Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Arthritis Res Ther. 2003;5(3):136-8. doi: 10.1186/ar755. Epub 2003 Mar 27.
BLyS/BAFF (B-lymphocyte stimulator/B-cell activating factor) is a vital B-cell survival factor. Overexpression of BLyS in mice may lead to systemic-lupus-erythematosus-like (SLE-like) disease, and BLyS overexpression is common in human SLE. Treatment of SLE-prone mice with a BLyS antagonist ameliorates disease progression and enhances survival, making BLyS an attractive therapeutic target in human disease. However, several unresolved issues remain, including what is the contributory role of APRIL (a tumor-necrosis-factor superfamily member related to BLyS) in the 'autoimmunogenic' effects of BLyS, identification of the 'optimal' BLyS antagonist, and identification of those SLE patients most likely to benefit from BLyS antagonist therapy.
B淋巴细胞刺激因子/ B细胞激活因子（BLyS/BAFF）是一种重要的B细胞存活因子。小鼠体内BLyS的过度表达可能会导致类似系统性红斑狼疮（SLE）的疾病，而BLyS的过度表达在人类SLE中很常见。用BLyS拮抗剂治疗易患SLE的小鼠可改善疾病进展并提高生存率，这使得BLyS成为人类疾病中一个有吸引力的治疗靶点。然而，仍有几个未解决的问题，包括APRIL（一种与BLyS相关的肿瘤坏死因子超家族成员）在BLyS的“自身免疫原性”效应中的作用、“最佳”BLyS拮抗剂的鉴定，以及确定那些最有可能从BLyS拮抗剂治疗中受益的SLE患者。
